title: Targeting cancer stem-like cells using dietary-derived agents - Where are we now?
abstract: Diet has been linked to an overwhelming proportion of cancers. Current chemotherapy and targeted therapies are limited by toxicity and the development of resistance against these treatments results in cancer recurrence or progression. In vitro evidence indicates that a number of dietary-derived agents have activity against a highly tumorigenic, chemoradiotherapy resistant population of cells within a tumour. This population is associated with cancer recurrence and is therefore clinically significant. Targeting this subpopulation, termed cancer stem-like cells with dietary-derived agents provides a potentially low toxicity strategy to enhance current treatment regimens. In addition, dietary-derived compounds also provide a novel approach to cancer prevention strategies. This review focusses on selected diet-derived agents that have been shown to specifically target cancer stem-like cells using in vivo models, or in clinical trials. Furthermore, the potential limitations of these studies are discussed, and areas of research that need to be addressed to allow successful translation of dietary-derived agents to the clinical arena are highlighted.
authors.affiliation: Department of Cancer Studies, University of Leicester, Leicester, UK.|Department of Molecular and Cell Biology, University of Leicester, Leicester, UK.
authors.forename: Sameena
authors.initials: S
authors.lastname: Khan
authors.affiliation: Department of Cancer Studies, University of Leicester, Leicester, UK.
authors.forename: Ankur
authors.initials: A
authors.lastname: Karmokar
authors.affiliation: Department of Cancer Studies, University of Leicester, Leicester, UK.
authors.forename: Lynne
authors.initials: L
authors.lastname: Howells
authors.affiliation: Department of Cancer Studies, University of Leicester, Leicester, UK.
authors.forename: Anne L
authors.initials: AL
authors.lastname: Thomas
authors.affiliation: Department of Molecular and Cell Biology, University of Leicester, Leicester, UK.
authors.forename: Richard
authors.initials: R
authors.lastname: Bayliss
authors.affiliation: Department of Cancer Studies, University of Leicester, Leicester, UK.
authors.forename: Andreas
authors.initials: A
authors.lastname: Gescher
authors.affiliation: Department of Cancer Studies, University of Leicester, Leicester, UK.
authors.forename: Karen
authors.initials: K
authors.lastname: Brown
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology; D002392:Catechin / Q000031:analogs & derivatives / Q000494:pharmacology; D045744:Cell Line, Tumor; D003474:Curcumin / Q000494:pharmacology; D004032:Diet; D004195:Disease Models, Animal; D005419:Flavonoids / Q000494:pharmacology; D006801:Humans; D017879:Isothiocyanates / Q000494:pharmacology; D009369:Neoplasms / Q000188:drug therapy*; D014411:Neoplastic Stem Cells / Q000187:drug effects*; D016032:Randomized Controlled Trials as Topic; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology; D013454:Sulfoxides; D014801:Vitamin A / Q000494:pharmacology
chemical_list: D016588:Anticarcinogenic Agents; D005419:Flavonoids; D017879:Isothiocyanates; D013267:Stilbenes; D013454:Sulfoxides; D014801:Vitamin A; D002392:Catechin; C045651:epigallocatechin gallate; C016766:sulforaphane; D003474:Curcumin; D000077185:Resveratrol
keywords: Cancer stem cells; Chemoprevention; Curcumin; In vivo; Resveratrol